Disease reactivation after switching from natalizumab to daclizumab
Discontinuation of natalizumab can lead to severe rebound of disease activity in patients with relapsing–remitting multiple sclerosis (RRMS); nevertheless, the treatment regimen in this clinical situation remains controversial. We report the case of a 25-year-old male patient with RRMS who was clini...
Gespeichert in:
| Veröffentlicht in: | Journal of neurology 2017-12, Vol.264 (12), p.2491-2494 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 2494 |
|---|---|
| container_issue | 12 |
| container_start_page | 2491 |
| container_title | Journal of neurology |
| container_volume | 264 |
| creator | Uphaus, Timo Oberwittler, Christoph Groppa, Sergiu Zipp, Frauke Bittner, Stefan |
| description | Discontinuation of natalizumab can lead to severe rebound of disease activity in patients with relapsing–remitting multiple sclerosis (RRMS); nevertheless, the treatment regimen in this clinical situation remains controversial. We report the case of a 25-year-old male patient with RRMS who was clinically stable under 3 years of natalizumab before treatment was stopped due to progressive multifocal leucencephalopathy (PML) safety concerns. After initiation of daclizumab, the patient suffered from disease reactivation, which was ultimately controlled by intravenous methylprednisolone and alemtuzumab treatment. Therefore, in some patients, daclizumab might not be sufficient to control disease activity after discontinuing natalizumab treatment. |
| doi_str_mv | 10.1007/s00415-017-8622-9 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1947099606</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1947099606</sourcerecordid><originalsourceid>FETCH-LOGICAL-c372t-94f452a6b988cc6168e3983b6de4862418446c3c55da455785a87904af1f7e343</originalsourceid><addsrcrecordid>eNp1kE1LAzEQhoMotlZ_gBdZ8OJldZJMsslR6icIXvQc0jRbt3R3a7Kr6K83ZauI4GkY5pl3hoeQYwrnFKC4iABIRQ60yJVkLNc7ZEyRs5yi0LtkDBwhF1zgiBzEuAQAlQb7ZMSULgQCjMn0qoreRp8Fb11XvdmuapvMlp0PWXyvOvdSNYusDG2dNbazq-qzr-0s69psbt22OyR7pV1Ff7StE_J8c_00vcsfHm_vp5cPueMF63KNJQpm5Uwr5ZykUnmuFZ_Jucf0PlKFKB13QswtClEoYVWhAW1Jy8Jz5BNyNuSuQ_va-9iZuorOr1a28W0fDdVYgNYSZEJP_6DLtg9N-i5RElEoxmii6EC50MYYfGnWoapt-DAUzMawGQybZNhsDBuddk62yf2s9vOfjW-lCWADENOoWfjw6_S_qV9TcYR1</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1964458221</pqid></control><display><type>article</type><title>Disease reactivation after switching from natalizumab to daclizumab</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Uphaus, Timo ; Oberwittler, Christoph ; Groppa, Sergiu ; Zipp, Frauke ; Bittner, Stefan</creator><creatorcontrib>Uphaus, Timo ; Oberwittler, Christoph ; Groppa, Sergiu ; Zipp, Frauke ; Bittner, Stefan</creatorcontrib><description>Discontinuation of natalizumab can lead to severe rebound of disease activity in patients with relapsing–remitting multiple sclerosis (RRMS); nevertheless, the treatment regimen in this clinical situation remains controversial. We report the case of a 25-year-old male patient with RRMS who was clinically stable under 3 years of natalizumab before treatment was stopped due to progressive multifocal leucencephalopathy (PML) safety concerns. After initiation of daclizumab, the patient suffered from disease reactivation, which was ultimately controlled by intravenous methylprednisolone and alemtuzumab treatment. Therefore, in some patients, daclizumab might not be sufficient to control disease activity after discontinuing natalizumab treatment.</description><identifier>ISSN: 0340-5354</identifier><identifier>EISSN: 1432-1459</identifier><identifier>DOI: 10.1007/s00415-017-8622-9</identifier><identifier>PMID: 28975400</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Adult ; Anti-Inflammatory Agents - therapeutic use ; Antibodies, Monoclonal, Humanized - adverse effects ; Drug Substitution - adverse effects ; Humans ; Immunoglobulin G - adverse effects ; Immunologic Factors - therapeutic use ; Immunotherapy ; Intravenous administration ; Magnetic Resonance Imaging ; Male ; Medicine ; Medicine & Public Health ; Methylprednisolone ; Methylprednisolone - therapeutic use ; Monoclonal antibodies ; Multiple sclerosis ; Multiple Sclerosis, Relapsing-Remitting - chemically induced ; Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging ; Multiple Sclerosis, Relapsing-Remitting - drug therapy ; Natalizumab - therapeutic use ; Neurology ; Neuroradiology ; Neurosciences ; Short Commentary</subject><ispartof>Journal of neurology, 2017-12, Vol.264 (12), p.2491-2494</ispartof><rights>Springer-Verlag GmbH Germany 2017</rights><rights>Journal of Neurology is a copyright of Springer, (2017). All Rights Reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c372t-94f452a6b988cc6168e3983b6de4862418446c3c55da455785a87904af1f7e343</citedby><cites>FETCH-LOGICAL-c372t-94f452a6b988cc6168e3983b6de4862418446c3c55da455785a87904af1f7e343</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00415-017-8622-9$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00415-017-8622-9$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27922,27923,41486,42555,51317</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/28975400$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Uphaus, Timo</creatorcontrib><creatorcontrib>Oberwittler, Christoph</creatorcontrib><creatorcontrib>Groppa, Sergiu</creatorcontrib><creatorcontrib>Zipp, Frauke</creatorcontrib><creatorcontrib>Bittner, Stefan</creatorcontrib><title>Disease reactivation after switching from natalizumab to daclizumab</title><title>Journal of neurology</title><addtitle>J Neurol</addtitle><addtitle>J Neurol</addtitle><description>Discontinuation of natalizumab can lead to severe rebound of disease activity in patients with relapsing–remitting multiple sclerosis (RRMS); nevertheless, the treatment regimen in this clinical situation remains controversial. We report the case of a 25-year-old male patient with RRMS who was clinically stable under 3 years of natalizumab before treatment was stopped due to progressive multifocal leucencephalopathy (PML) safety concerns. After initiation of daclizumab, the patient suffered from disease reactivation, which was ultimately controlled by intravenous methylprednisolone and alemtuzumab treatment. Therefore, in some patients, daclizumab might not be sufficient to control disease activity after discontinuing natalizumab treatment.</description><subject>Adult</subject><subject>Anti-Inflammatory Agents - therapeutic use</subject><subject>Antibodies, Monoclonal, Humanized - adverse effects</subject><subject>Drug Substitution - adverse effects</subject><subject>Humans</subject><subject>Immunoglobulin G - adverse effects</subject><subject>Immunologic Factors - therapeutic use</subject><subject>Immunotherapy</subject><subject>Intravenous administration</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Methylprednisolone</subject><subject>Methylprednisolone - therapeutic use</subject><subject>Monoclonal antibodies</subject><subject>Multiple sclerosis</subject><subject>Multiple Sclerosis, Relapsing-Remitting - chemically induced</subject><subject>Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging</subject><subject>Multiple Sclerosis, Relapsing-Remitting - drug therapy</subject><subject>Natalizumab - therapeutic use</subject><subject>Neurology</subject><subject>Neuroradiology</subject><subject>Neurosciences</subject><subject>Short Commentary</subject><issn>0340-5354</issn><issn>1432-1459</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2017</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp1kE1LAzEQhoMotlZ_gBdZ8OJldZJMsslR6icIXvQc0jRbt3R3a7Kr6K83ZauI4GkY5pl3hoeQYwrnFKC4iABIRQ60yJVkLNc7ZEyRs5yi0LtkDBwhF1zgiBzEuAQAlQb7ZMSULgQCjMn0qoreRp8Fb11XvdmuapvMlp0PWXyvOvdSNYusDG2dNbazq-qzr-0s69psbt22OyR7pV1Ff7StE_J8c_00vcsfHm_vp5cPueMF63KNJQpm5Uwr5ZykUnmuFZ_Jucf0PlKFKB13QswtClEoYVWhAW1Jy8Jz5BNyNuSuQ_va-9iZuorOr1a28W0fDdVYgNYSZEJP_6DLtg9N-i5RElEoxmii6EC50MYYfGnWoapt-DAUzMawGQybZNhsDBuddk62yf2s9vOfjW-lCWADENOoWfjw6_S_qV9TcYR1</recordid><startdate>20171201</startdate><enddate>20171201</enddate><creator>Uphaus, Timo</creator><creator>Oberwittler, Christoph</creator><creator>Groppa, Sergiu</creator><creator>Zipp, Frauke</creator><creator>Bittner, Stefan</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20171201</creationdate><title>Disease reactivation after switching from natalizumab to daclizumab</title><author>Uphaus, Timo ; Oberwittler, Christoph ; Groppa, Sergiu ; Zipp, Frauke ; Bittner, Stefan</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c372t-94f452a6b988cc6168e3983b6de4862418446c3c55da455785a87904af1f7e343</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2017</creationdate><topic>Adult</topic><topic>Anti-Inflammatory Agents - therapeutic use</topic><topic>Antibodies, Monoclonal, Humanized - adverse effects</topic><topic>Drug Substitution - adverse effects</topic><topic>Humans</topic><topic>Immunoglobulin G - adverse effects</topic><topic>Immunologic Factors - therapeutic use</topic><topic>Immunotherapy</topic><topic>Intravenous administration</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Methylprednisolone</topic><topic>Methylprednisolone - therapeutic use</topic><topic>Monoclonal antibodies</topic><topic>Multiple sclerosis</topic><topic>Multiple Sclerosis, Relapsing-Remitting - chemically induced</topic><topic>Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging</topic><topic>Multiple Sclerosis, Relapsing-Remitting - drug therapy</topic><topic>Natalizumab - therapeutic use</topic><topic>Neurology</topic><topic>Neuroradiology</topic><topic>Neurosciences</topic><topic>Short Commentary</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Uphaus, Timo</creatorcontrib><creatorcontrib>Oberwittler, Christoph</creatorcontrib><creatorcontrib>Groppa, Sergiu</creatorcontrib><creatorcontrib>Zipp, Frauke</creatorcontrib><creatorcontrib>Bittner, Stefan</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Uphaus, Timo</au><au>Oberwittler, Christoph</au><au>Groppa, Sergiu</au><au>Zipp, Frauke</au><au>Bittner, Stefan</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Disease reactivation after switching from natalizumab to daclizumab</atitle><jtitle>Journal of neurology</jtitle><stitle>J Neurol</stitle><addtitle>J Neurol</addtitle><date>2017-12-01</date><risdate>2017</risdate><volume>264</volume><issue>12</issue><spage>2491</spage><epage>2494</epage><pages>2491-2494</pages><issn>0340-5354</issn><eissn>1432-1459</eissn><abstract>Discontinuation of natalizumab can lead to severe rebound of disease activity in patients with relapsing–remitting multiple sclerosis (RRMS); nevertheless, the treatment regimen in this clinical situation remains controversial. We report the case of a 25-year-old male patient with RRMS who was clinically stable under 3 years of natalizumab before treatment was stopped due to progressive multifocal leucencephalopathy (PML) safety concerns. After initiation of daclizumab, the patient suffered from disease reactivation, which was ultimately controlled by intravenous methylprednisolone and alemtuzumab treatment. Therefore, in some patients, daclizumab might not be sufficient to control disease activity after discontinuing natalizumab treatment.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>28975400</pmid><doi>10.1007/s00415-017-8622-9</doi><tpages>4</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0340-5354 |
| ispartof | Journal of neurology, 2017-12, Vol.264 (12), p.2491-2494 |
| issn | 0340-5354 1432-1459 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1947099606 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adult Anti-Inflammatory Agents - therapeutic use Antibodies, Monoclonal, Humanized - adverse effects Drug Substitution - adverse effects Humans Immunoglobulin G - adverse effects Immunologic Factors - therapeutic use Immunotherapy Intravenous administration Magnetic Resonance Imaging Male Medicine Medicine & Public Health Methylprednisolone Methylprednisolone - therapeutic use Monoclonal antibodies Multiple sclerosis Multiple Sclerosis, Relapsing-Remitting - chemically induced Multiple Sclerosis, Relapsing-Remitting - diagnostic imaging Multiple Sclerosis, Relapsing-Remitting - drug therapy Natalizumab - therapeutic use Neurology Neuroradiology Neurosciences Short Commentary |
| title | Disease reactivation after switching from natalizumab to daclizumab |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-09T22%3A59%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Disease%20reactivation%20after%20switching%20from%20natalizumab%20to%20daclizumab&rft.jtitle=Journal%20of%20neurology&rft.au=Uphaus,%20Timo&rft.date=2017-12-01&rft.volume=264&rft.issue=12&rft.spage=2491&rft.epage=2494&rft.pages=2491-2494&rft.issn=0340-5354&rft.eissn=1432-1459&rft_id=info:doi/10.1007/s00415-017-8622-9&rft_dat=%3Cproquest_cross%3E1947099606%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1964458221&rft_id=info:pmid/28975400&rfr_iscdi=true |